Opinion|Videos|February 13, 2025
Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase
Panelists discuss how chronic spontaneous urticaria (CSU) treatment targets multiple pathways through antihistamines, anti-IgE therapy, and BTK inhibitors, with BTK emerging as a key target.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What mechanisms and targets are currently being utilized or studied for the treatment of CSU?
- Why are so many patients (more than half) with CSU unable to achieve adequate control with antihistamines alone?
- What role does BTK play in the pathogenesis of CSU?
- BTK signaling is involved in pathways that lead to the degranulation of skin mast cells, which are key pathogenic drivers of CSU.
- BTK also presents in B cells and basophils, the latter of which activate and degranulate similarly to mast cells.
Advertisement
Related to this article
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5